Development and characterization of proteasome inhibitors
Kyung Bo Kim1, Fabiana N Fonseca, Craig M Crews
1Department of Molecular, Cell, and Developmental Biology, Yale University, New Haven, Connecticut, USA.
Methods in Enzymology
|December 13, 2005
Summary
Epoxomicin and eponemycin are natural products that inhibit proteasomes, crucial for understanding proteasome function and developing new cancer drugs. Their unique alpha,beta-epoxyketone structure targets proteasomes effectively.
Area of Science:
- Biochemistry
- Molecular Biology
- Medicinal Chemistry
Background:
- Proteasome inhibitors are vital for understanding proteasome function and developing therapeutics.
- Natural products like epoxomicin and eponemycin offer unique structural motifs for drug development.
Purpose of the Study:
- To detail the synthesis of alpha',beta'-epoxyketone natural product epoxomicin and its derivatives.
- To explore the development of novel proteasome inhibitors based on these compounds.
Main Methods:
- Structural studies of the proteasome-epoxomicin complex.
- Detailed synthetic procedures for epoxomicin and its derivatives.
Main Results:
- Epoxomicin and eponemycin target proteasomes via their alpha,beta-epoxyketone pharmacophore.
- The pharmacophore forms a unique morpholino ring with the catalytic Thr-1 of the 20S proteasome, conferring specificity.
Conclusions:
- The alpha,beta-epoxyketone pharmacophore is key to the specificity and antitumor activity of epoxomicin and eponemycin.
- Facile synthesis of these peptides opens avenues for developing novel, potent proteasome inhibitors.
More Related Videos
Related Concept Videos
01:17The Proteasome Structure
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
01:13The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
02:18The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...